title: A new mode of RAF autoregulation: a further complication in the inhibitor paradox.
abstract: ERK pathway activation in cells expressing wild-type BRAF is a well-reported, clinically-relevant adverse effect of the otherwise impressive response of BRAF(V600E)-mutated melanomas to RAF inhibitors. In this issue of Cancer Cell, Holderfield and colleagues show that RAF autoinhibition underpins this paradox, further complicating therapeutic strategies centered around RAF.
authors.affiliation: Department of Biochemistry, University of Leicester, Lancaster Road, Leicester LE1 9HN, UK.
authors.forename: Fiona
authors.initials: F
authors.lastname: Hey
authors.forename: Catrin
authors.initials: C
authors.lastname: Pritchard
mesh_terms: D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D048490:raf Kinases / Q000037:antagonists & inhibitors*
chemical_list: D048490:raf Kinases